Home LiteratureArticle Details
PMID: 21935886 Published · ppublish English Journal Article Review

Posttranscriptional regulation of cancer traits by HuR.

Wiley interdisciplinary reviews. RNA ·Vol. 1 ·No. 2 ·2010-00-00 ·Pages 214-29

Abdelmohsen K, Gorospe M

Abstract

Cancer-related gene expression programs are strongly influenced by posttranscriptional mechanisms. The RNA-binding protein HuR is highly abundant in many cancers. Numerous HuR-regulated mRNAs encode proteins implicated in carcinogenesis. Here, we review the collections of HuR target mRNAs that encode proteins responsible for implementing five major cancer traits. By interacting with specific mRNA subsets, HuR enhances the levels of proteins that (1) promote cell proliferation, (2) increase cell survival, (3) elevate local angiogenesis, (4) help the cancer cell evade immune recognition, and (5) facilitate cancer cell invasion and metastasis. We propose that HuR exerts a tumorigenic function by enabling these cancer phenotypes. We discuss evidence that links HuR to several specific cancers and suggests its potential usefulness in cancer diagnosis, prognosis, and therapy.

MeSH Terms
Adaptive Immunity/genetics,physiology Animals Cell Proliferation Cell Survival/genetics,physiology ELAV Proteins/genetics,metabolism,physiology Gene Expression Regulation, Neoplastic Humans Models, Biological Neoplasms/genetics,metabolism Quantitative Trait, Heritable RNA Processing, Post-Transcriptional
Chemicals
ELAV Proteins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Abdelmohsen Kotb
LCMB, NIA-IRP, NIH, Baltimore, MD 21224, USA. [email protected]
Gorospe Myriam
References (173)
173 references, click to expand
  1. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression.
    Genes Chromosomes Cancer. 1998 May;22(1):66-71 PMID: 9591636
  2. The yin and yang of the exosome.
    Trends Cell Biol. 2002 Feb;12(2):90-6 PMID: 11849973
  3. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2.
    Mol Cell Biol. 2003 Oct;23(20):7177-88 PMID: 14517288
  4. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels.
    Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20297-302 PMID: 19088191
  5. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal.
    Cell. 1991 Oct 18;67(2):325-33 PMID: 1655278
  6. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E.
    Mol Cell Biol. 1997 Jan;17(1):453-9 PMID: 8972226
  7. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs.
    Cancer Res. 2001 Mar 1;61(5):2154-61 PMID: 11280780
  8. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR.
    Mol Cell Biol. 2003 Jul;23(14):4901-16 PMID: 12832476
  9. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
    Cancer Res. 2004 Jan 1;64(1):189-95 PMID: 14729623
  10. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs.
    EMBO J. 2004 Aug 4;23(15):3092-102 PMID: 15257295
  11. Prognostic role of HuR in hereditary breast cancer.
    Clin Cancer Res. 2007 Dec 1;13(23):6959-63 PMID: 18056170
  12. Functional role of p21 during the cellular response to stress.
    Gene Expr. 1999;7(4-6):377-85 PMID: 10440238
  13. The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies.
    RNA. 2003 Oct;9(10):1171-3 PMID: 13130130
  14. RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.
    Cancer Metastasis Rev. 2007 Dec;26(3-4):675-83 PMID: 17828469
  15. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis.
    Cancer Res. 2009 Jun 15;69(12):5168-76 PMID: 19491267
  16. Expression genetics in cancer: shifting the focus from DNA to RNA.
    Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):952-5 PMID: 9023363
  17. p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint.
    Mol Cell Biol. 2009 Aug;29(16):4341-51 PMID: 19528229
  18. Cell cycle, CDKs and cancer: a changing paradigm.
    Nat Rev Cancer. 2009 Mar;9(3):153-66 PMID: 19238148
  19. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.
    Int J Cancer. 2005 Mar 1;113(6):911-9 PMID: 15514971
  20. Vascular endothelial growth factor (VEGF) and its receptors.
    FASEB J. 1999 Jan;13(1):9-22 PMID: 9872925
  21. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
    Nat Rev Cancer. 2007 Jun;7(6):415-28 PMID: 17508028
  22. VEGFs, receptors and angiogenesis.
    Semin Cancer Biol. 1999 Jun;9(3):211-20 PMID: 10343072
  23. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
    Clin Cancer Res. 2005 Jun 1;11(11):3974-86 PMID: 15930332
  24. Dual-specificity MAP kinase phosphatases (MKPs) and cancer.
    Cancer Metastasis Rev. 2008 Jun;27(2):253-61 PMID: 18330678
  25. ERBB receptors and cancer: the complexity of targeted inhibitors.
    Nat Rev Cancer. 2005 May;5(5):341-54 PMID: 15864276
  26. Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
    J Oral Pathol Med. 2007 May;36(5):297-303 PMID: 17448140
  27. Nuclear HuR accumulation through phosphorylation by Cdk1.
    Genes Dev. 2008 Jul 1;22(13):1804-15 PMID: 18593881
  28. Prognostic significance of cyclin A in gastric cancer.
    Int J Cancer. 2006 Oct 15;119(8):1897-901 PMID: 16708383
  29. Regulation of innate immune response by MAP kinase phosphatase-1.
    Cell Signal. 2007 Jul;19(7):1372-82 PMID: 17512700
  30. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA.
    Mol Cell Biol. 2008 Apr;28(8):2608-25 PMID: 18285462
  31. Mcl-1.
    Int J Biochem Cell Biol. 2005 Feb;37(2):267-71 PMID: 15474972
  32. Control of thymic T cell maturation, deletion and egress by the RNA-binding protein HuR.
    J Immunol. 2009 Jun 1;182(11):6779-88 PMID: 19454673
  33. Phosphorylated HuR shuttles in cycles.
    Cell Cycle. 2008 Oct;7(20):3124-6 PMID: 18927508
  34. From birth to death: the complex lives of eukaryotic mRNAs.
    Science. 2005 Sep 2;309(5740):1514-8 PMID: 16141059
  35. Analysis of nitric oxide-stabilized mRNAs in human fibroblasts reveals HuR-dependent heme oxygenase 1 upregulation.
    Mol Cell Biol. 2009 May;29(10):2622-35 PMID: 19289500
  36. Role of transforming growth factor Beta in human cancer.
    J Clin Oncol. 2005 Mar 20;23(9):2078-93 PMID: 15774796
  37. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells.
    Cancer Res. 2006 Aug 15;66(16):7948-56 PMID: 16912169
  38. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90.
    Mol Cell Biol. 2008 Jul;28(14):4562-75 PMID: 18490444
  39. Matrix metalloproteinases and tumor metastasis.
    Cancer Metastasis Rev. 2006 Mar;25(1):9-34 PMID: 16680569
  40. The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements.
    EMBO J. 2002 Jan 15;21(1-2):165-74 PMID: 11782436
  41. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs.
    Cell. 2001 Nov 16;107(4):451-64 PMID: 11719186
  42. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Cancer Res. 2009 Jun 1;69(11):4567-72 PMID: 19487279
  43. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
    Cell. 1996 Aug 9;86(3):353-64 PMID: 8756718
  44. HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.
    Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):93-8 PMID: 19281587
  45. Stabilization of Snail by HuR in the process of hydrogen peroxide induced cell migration.
    Biochem Biophys Res Commun. 2007 Apr 27;356(1):318-21 PMID: 17350594
  46. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR.
    Clin Cancer Res. 2005 Oct 15;11(20):7362-8 PMID: 16243808
  47. The urokinase receptor as an entertainer of signal transduction.
    Front Biosci (Landmark Ed). 2009 Jan 01;14:4575-87 PMID: 19273372
  48. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation.
    EMBO J. 2000 May 15;19(10):2340-50 PMID: 10811625
  49. HuR and mRNA stability.
    Cell Mol Life Sci. 2001 Feb;58(2):266-77 PMID: 11289308
  50. Cytoplasmic foci are sites of mRNA decay in human cells.
    J Cell Biol. 2004 Apr;165(1):31-40 PMID: 15067023
  51. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence.
    Biol Chem. 2008 Mar;389(3):243-55 PMID: 18177264
  52. Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence.
    Mol Cell Biol. 2001 Sep;21(17):5889-98 PMID: 11486028
  53. Identification of a target RNA motif for RNA-binding protein HuR.
    Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2987-92 PMID: 14981256
  54. Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA.
    Biochem Biophys Res Commun. 2004 Sep 17;322(2):644-51 PMID: 15325278
  55. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies.
    Eur Urol. 2009 Jul;56(1):105-12 PMID: 18468781
  56. Phosphorylation of HuR by Chk2 regulates SIRT1 expression.
    Mol Cell. 2007 Feb 23;25(4):543-57 PMID: 17317627
  57. Tissue- and age-dependent expression of RNA-binding proteins that influence mRNA turnover and translation.
    Aging (Albany NY). 2009 Jul 26;1(8):681-98 PMID: 20157551
  58. Aberrant regulation of messenger RNA 3'-untranslated region in human cancer.
    Cell Oncol. 2007;29(1):1-17 PMID: 17429137
  59. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR.
    Genes Dev. 2002 Dec 1;16(23):3087-99 PMID: 12464637
  60. TGF-beta signaling in tumor suppression and cancer progression.
    Nat Genet. 2001 Oct;29(2):117-29 PMID: 11586292
  61. Role of TGF-beta in immune-evasion of cancer.
    Microsc Res Tech. 2001 Feb 15;52(4):387-95 PMID: 11170297
  62. Cancer and cyclooxygenase-2 (COX-2) inhibition.
    Curr Pharm Des. 2004;10(6):627-34 PMID: 14965325
  63. Cyclin E in normal and neoplastic cell cycles.
    Oncogene. 2005 Apr 18;24(17):2776-86 PMID: 15838514
  64. Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis.
    J Cell Biol. 2008 Jan 14;180(1):113-27 PMID: 18180367
  65. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.
    J Clin Invest. 2001 Dec;108(11):1657-65 PMID: 11733561
  66. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis.
    Cancer. 2008 Nov 15;113(10):2761-9 PMID: 18831511
  67. Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
    Cancer Res. 2008 Feb 1;68(3):631-4 PMID: 18245460
  68. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
    Nat Chem Biol. 2007 Aug;3(8):508-15 PMID: 17632515
  69. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
    Int J Oncol. 2008 Feb;32(2):341-7 PMID: 18202756
  70. Factors interacting with HIF-1alpha mRNA: novel therapeutic targets.
    Curr Pharm Des. 2009;15(33):3853-60 PMID: 19671045
  71. Uterine cervical carcinoma: role of matrix metalloproteinases (review).
    Int J Oncol. 2009 Apr;34(4):897-903 PMID: 19287946
  72. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.
    Nat Rev Cancer. 2006 Jul;6(7):506-20 PMID: 16794634
  73. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence.
    Carcinogenesis. 2008 Nov;29(11):2053-61 PMID: 18687667
  74. Delineation of mRNA export pathways by the use of cell-permeable peptides.
    Science. 2001 Nov 30;294(5548):1895-901 PMID: 11729309
  75. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines.
    Int J Cancer. 1994 Oct 15;59(2):191-5 PMID: 7927918
  76. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.
    Cancer Cell. 2003 Mar;3(3):219-31 PMID: 12676581
  77. Modification at HuR(S242) alters HuR localization and proliferative influence.
    Cell Cycle. 2008 Nov 1;7(21):3371-7 PMID: 18948743
  78. Apoptotic signaling by c-MYC.
    Oncogene. 2008 Oct 27;27(50):6462-72 PMID: 18955973
  79. Relief of microRNA-mediated translational repression in human cells subjected to stress.
    Cell. 2006 Jun 16;125(6):1111-24 PMID: 16777601
  80. Cellular senescence: when bad things happen to good cells.
    Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40 PMID: 17667954
  81. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.
    Cell. 1994 Jul 15;78(1):59-66 PMID: 8033212
  82. Highly selective actions of HuR in antagonizing AU-rich element-mediated mRNA destabilization.
    Mol Cell Biol. 2002 Oct;22(20):7268-78 PMID: 12242302
  83. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.
    Cancer Res. 2006 Jan 1;66(1):6-9 PMID: 16397206
  84. Elevation of cyclin B1, active cdc2, and HuR in cervical neoplasia with human papillomavirus type 18 infection.
    Cancer Lett. 2006 Feb 8;232(2):170-8 PMID: 16458113
  85. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.
    Cell. 2002 May 3;109(3):321-34 PMID: 12015982
  86. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.
    Oncogene. 2009 Mar 5;28(9):1176-86 PMID: 19151756
  87. RNA-binding proteins implicated in the hypoxic response.
    J Cell Mol Med. 2009 Sep;13(9A):2759-69 PMID: 19583805
  88. HIF-1: mediator of physiological and pathophysiological responses to hypoxia.
    J Appl Physiol (1985). 2000 Apr;88(4):1474-80 PMID: 10749844
  89. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8354-9 PMID: 12821781
  90. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery.
    Mol Cell. 2004 Jun 4;14(5):571-83 PMID: 15175153
  91. Posttranscriptional orchestration of an anti-apoptotic program by HuR.
    Cell Cycle. 2007 Jun 1;6(11):1288-92 PMID: 17534146
  92. Cyclin D1: polymorphism, aberrant splicing and cancer risk.
    Oncogene. 2006 Mar 13;25(11):1620-8 PMID: 16550162
  93. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
    Cancer Res. 2008 Nov 15;68(22):9469-78 PMID: 19010922
  94. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
    Clin Cancer Res. 2004 Aug 15;10(16):5572-9 PMID: 15328199
  95. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.
    Oncogene. 2008 Oct 16;27(47):6151-63 PMID: 18641687
  96. Cyclin A in cell cycle control and cancer.
    Cell Mol Life Sci. 2002 Aug;59(8):1317-26 PMID: 12363035
  97. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.
    Cancer Res. 2003 Nov 15;63(22):7591-4 PMID: 14633672
  98. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR.
    J Biol Chem. 1998 Mar 13;273(11):6417-23 PMID: 9497373
  99. Cellular senescence: its role in tumor suppression and aging.
    Cancer Sci. 2009 May;100(5):792-7 PMID: 19302284
  100. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.
    Clin Cancer Res. 2006 Apr 15;12(8):2404-13 PMID: 16638845
  101. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.
    Science. 1997 Feb 21;275(5303):1129-32 PMID: 9027314
  102. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.
    Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486-90 PMID: 2137615
  103. Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR.
    Mol Cell Biol. 2006 Apr;26(8):3295-307 PMID: 16581801
  104. Anticancer potential of silymarin: from bench to bed side.
    Anticancer Res. 2006 Nov-Dec;26(6B):4457-98 PMID: 17201169
  105. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition.
    J Biol Chem. 2008 Jul 4;283(27):19077-84 PMID: 18463097
  106. Role of the RNA-binding protein HuR in colon carcinogenesis.
    Oncogene. 2003 Oct 16;22(46):7146-54 PMID: 14562043
  107. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
    Cancer Biol Ther. 2008 Sep;7(9):1496-506 PMID: 18769129
  108. Ubiquitin-mediated proteolysis of HuR by heat shock.
    EMBO J. 2009 May 6;28(9):1271-82 PMID: 19322201
  109. Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha.
    EMBO J. 2005 May 18;24(10):1852-62 PMID: 15861128
  110. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.
    Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8022-6 PMID: 8058751
  111. Vascular-specific growth factors and blood vessel formation.
    Nature. 2000 Sep 14;407(6801):242-8 PMID: 11001067
  112. RNA regulons: coordination of post-transcriptional events.
    Nat Rev Genet. 2007 Jul;8(7):533-43 PMID: 17572691
  113. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice.
    J Clin Invest. 2009 Dec;119(12):3530-43 PMID: 19884656
  114. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells.
    Nucleic Acids Res. 2006;34(14):3988-99 PMID: 16914445
  115. Surfing on prothymosin alpha proliferation and anti-apoptotic properties.
    Neoplasma. 2006;53(2):92-6 PMID: 16575463
  116. Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase.
    Mol Cell Biol. 2001 Sep;21(17):5778-89 PMID: 11486017
  117. Expression of HuR in Merkel cell carcinoma and in normal skin.
    J Cutan Pathol. 2008 Jan;35(1):10-4 PMID: 18095988
  118. AMP-activated kinase regulates cytoplasmic HuR.
    Mol Cell Biol. 2002 May;22(10):3425-36 PMID: 11971974
  119. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2.
    Mol Biol Cell. 2007 Jun;18(6):2137-48 PMID: 17392515
  120. Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer.
    Cancer Res Treat. 2009 Jun;41(2):87-92 PMID: 19707506
  121. ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR.
    J Biol Chem. 2003 Dec 19;278(51):51758-69 PMID: 14523003
  122. The human LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and Xrnl in distinct cytoplasmic foci.
    RNA. 2002 Dec;8(12):1489-501 PMID: 12515382
  123. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules.
    Cancer Cell. 2004 May;5(5):429-41 PMID: 15144951
  124. The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation.
    Nucleic Acids Res. 2005 May 24;33(9):2962-79 PMID: 15914670
  125. The critical role of the class III histone deacetylase SIRT1 in cancer.
    Cancer Res. 2009 Mar 1;69(5):1702-5 PMID: 19244112
  126. How does SIRT1 affect metabolism, senescence and cancer?
    Nat Rev Cancer. 2009 Feb;9(2):123-8 PMID: 19132007
  127. Transportin2 functions as importin and mediates nuclear import of HuR.
    Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2918-23 PMID: 14981248
  128. RNA-binding proteins in human genetic disease.
    Trends Genet. 2008 Aug;24(8):416-25 PMID: 18597886
  129. New functions for the matrix metalloproteinases in cancer progression.
    Nat Rev Cancer. 2002 Mar;2(3):161-74 PMID: 11990853
  130. HuR: post-transcriptional paths to malignancy.
    RNA Biol. 2005 Jan;2(1):11-3 PMID: 17132932
  131. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis.
    Oncology. 2009;76(6):420-9 PMID: 19420963
  132. Diverse molecular functions of Hu proteins.
    Cell Mol Life Sci. 2008 Oct;65(20):3168-81 PMID: 18581050
  133. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice.
    Cancer Res. 2002 Mar 1;62(5):1489-95 PMID: 11888925
  134. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
    J Clin Oncol. 2003 Sep 15;21(18):3391-401 PMID: 12885834
  135. Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase.
    J Biol Chem. 2002 Nov 22;277(47):44623-30 PMID: 12237300
  136. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling.
    J Cell Biol. 2005 Jun 20;169(6):871-84 PMID: 15967811
  137. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  138. VEGF as a key mediator of angiogenesis in cancer.
    Oncology. 2005;69 Suppl 3:4-10 PMID: 16301830
  139. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
    Gastroenterology. 2009 May;136(5):1669-79 PMID: 19208339
  140. Frequent amplification of the cyclin E gene in human gastric carcinomas.
    Jpn J Cancer Res. 1995 Jul;86(7):617-21 PMID: 7559076
  141. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
    Clin Cancer Res. 2008 Sep 15;14(18):5649-55 PMID: 18794071
  142. Integration of oxygen signaling at the consensus HRE.
    Sci STKE. 2005 Oct 18;2005(306):re12 PMID: 16234508
  143. Developmental expression of AUF1 and HuR, two c-myc mRNA binding proteins.
    Oncogene. 1998 Jul 2;16(26):3413-21 PMID: 9692549
  144. HuR recruits let-7/RISC to repress c-Myc expression.
    Genes Dev. 2009 Aug 1;23(15):1743-8 PMID: 19574298
  145. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.
    Science. 2003 Jan 10;299(5604):223-6 PMID: 12522243
  146. p27Kip1 overexpression causes apoptotic death of mammalian cells.
    Oncogene. 1997 Dec 11;15(24):2991-7 PMID: 9416843
  147. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR.
    Breast Cancer Res Treat. 2008 Sep;111(1):15-25 PMID: 17891453
  148. The role of cyclin E in cell proliferation, development and cancer.
    Prog Cell Cycle Res. 1997;3:171-91 PMID: 9552414
  149. Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
    Expert Rev Mol Med. 2009 Aug 27;11:e26 PMID: 19709449
  150. Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling.
    J Biol Chem. 2005 Aug 5;280(31):28230-40 PMID: 15946948
  151. Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.
    Mol Carcinog. 2010 Feb;49(2):130-40 PMID: 19777567
  152. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research.
    Biochem Cell Biol. 2008 Apr;86(2):178-83 PMID: 18443631
  153. Emerging roles of RNA and RNA-binding protein network in cancer cells.
    BMB Rep. 2009 Mar 31;42(3):125-30 PMID: 19335997
  154. RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha.
    Mol Cell Biol. 2008 Jan;28(1):93-107 PMID: 17967866
  155. HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells.
    Br J Cancer. 2009 Jun 16;100(12):1943-8 PMID: 19513080
  156. Global analysis of HuR-regulated gene expression in colon cancer systems of reducing complexity.
    Gene Expr. 2004;12(1):49-59 PMID: 15473260
  157. HuR regulates p21 mRNA stabilization by UV light.
    Mol Cell Biol. 2000 Feb;20(3):760-9 PMID: 10629032
  158. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells.
    Mol Cancer Res. 2009 Aug;7(8):1354-66 PMID: 19671677
  159. p21: structure and functions associated with cyclin-CDK binding.
    Prog Cell Cycle Res. 1997;3:125-34 PMID: 9552411
  160. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
    Mod Pathol. 2006 Sep;19(9):1261-9 PMID: 16799479
  161. Cyclooxygenase-2 in cancer and angiogenesis.
    Angiology. 2009 Apr-May;60(2):242-53 PMID: 18505747
  162. Physiological and pathophysiological functions of SIRT1.
    Mini Rev Med Chem. 2009 Mar;9(3):386-94 PMID: 19275731
  163. Matrix turnover.
    J Orthod. 2000 Sep;27(3):227-33 PMID: 11099555
  164. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2.
    J Biol Chem. 2003 Jul 4;278(27):25227-33 PMID: 12704185
  165. Transportins 1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR.
    RNA. 2004 Apr;10(4):590-9 PMID: 15037768
  166. HNS, a nuclear-cytoplasmic shuttling sequence in HuR.
    Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15293-8 PMID: 9860962
  167. MicroRNA-125a represses cell growth by targeting HuR in breast cancer.
    RNA Biol. 2009 Nov-Dec;6(5):575-83 PMID: 19875930
  168. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
    Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):205-22 PMID: 12784997
  169. The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes.
    Cell Cycle. 2009 Apr 1;8(7):960-1 PMID: 19287207
  170. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
    Cancer Res. 2005 Mar 15;65(6):2157-61 PMID: 15781626
  171. The role of hypoxia-inducible factors in cancer.
    Cell Mol Life Sci. 2007 Aug;64(16):2170-80 PMID: 17514355
  172. Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer.
    Am J Med Sci. 2009 Aug;338(2):96-106 PMID: 19680014
  173. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.
    Mol Cancer Ther. 2002 Jun;1(8):639-49 PMID: 12479224
Article Info
Journal
Wiley interdisciplinary reviews. RNA
Abbr.
Wiley Interdiscip Rev RNA
ISSN
1757-7012
DOI
10.1002/wrna.4
Email
[email protected]
Published
2010-00-00
Epub
2010-00-06
Pages
214-29
Language
English
Region
United States
NLM ID
101536955
PMCID
PMC3808850
Subset
IM
Grants
Intramural NIH HHS · Z01 AG000393-01 · United States
Intramural NIH HHS · Z01 AG000511-10 · United States
External Links
PubMed source DOI: 10.1002/wrna.4 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2